Profitability
Weight: 20%
F
0
- 5yr Avg ROIC -58.0%
- Operating Margin Trend -13498.82 pp/yr
SYRE
Spyre Therapeutics, Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 16.9 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -98.2%
- 5yr Share-Count CAGR 176.7%
Growth Quality
Weight: 15%
F
0
- Revenue-Growth Years (5) 0/5
Cash Generation
Weight: 15%
F
0
- 5yr FCF Margin -5003.0%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 20%
C
55
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 73.42
Stability
Weight: 15%
D+
39
- Negative-Revenue Years (5) 2/5
- Piotroski F-Score 2
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.Not enough curated-guru data to call a flow.